183 related articles for article (PubMed ID: 34382063)
1. The association between mean arterial pressure and outcomes in patients with cardiogenic shock: insights from the DOREMI trial.
Parlow S; Di Santo P; Mathew R; Jung RG; Simard T; Gillmore T; Mao B; Abdel-Razek O; Ramirez FD; Marbach JA; Dick A; Glover C; Russo JJ; Froeschl M; Labinaz M; Fernando SM; Hibbert B;
Eur Heart J Acute Cardiovasc Care; 2021 Oct; 10(7):712-720. PubMed ID: 34382063
[TBL] [Abstract][Full Text] [Related]
2. No sex-based difference in cardiogenic shock: A post-hoc analysis of the DOREMI trial.
Prosperi-Porta G; Motazedian P; Di Santo P; Jung RG; Parlow S; Abdel-Razek O; Simard T; Hutson J; Malhotra N; Fu A; Ramirez FD; Froeschl M; Mathew R; Hibbert B;
J Cardiol; 2022 Oct; 80(4):358-364. PubMed ID: 35725945
[TBL] [Abstract][Full Text] [Related]
3. Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial.
Di Santo P; Mathew R; Jung RG; Simard T; Skanes S; Mao B; Ramirez FD; Marbach JA; Abdel-Razek O; Motazedian P; Parlow S; Boczar KE; D'Egidio G; Hawken S; Bernick J; Wells GA; Dick A; So DY; Glover C; Russo JJ; McGuinty C; Hibbert B;
Crit Care; 2021 Aug; 25(1):289. PubMed ID: 34376218
[TBL] [Abstract][Full Text] [Related]
4. Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock.
Mathew R; Di Santo P; Jung RG; Marbach JA; Hutson J; Simard T; Ramirez FD; Harnett DT; Merdad A; Almufleh A; Weng W; Abdel-Razek O; Fernando SM; Kyeremanteng K; Bernick J; Wells GA; Chan V; Froeschl M; Labinaz M; Le May MR; Russo JJ; Hibbert B
N Engl J Med; 2021 Aug; 385(6):516-525. PubMed ID: 34347952
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis Comparing the Efficacy of Dobutamine Versus Milrinone in Acute Decompensated Heart Failure and Cardiogenic Shock.
Biswas S; Malik AH; Bandyopadhyay D; Gupta R; Goel A; Briasoulis A; Fonarow GC; Lanier GM; Naidu SS
Curr Probl Cardiol; 2023 Aug; 48(8):101245. PubMed ID: 35545181
[TBL] [Abstract][Full Text] [Related]
6. Implications of Myocardial Infarction on Management and Outcome in Cardiogenic Shock.
Jung RG; Di Santo P; Mathew R; Abdel-Razek O; Parlow S; Simard T; Marbach JA; Gillmore T; Mao B; Bernick J; Theriault-Lauzier P; Fu A; Lau L; Motazedian P; Russo JJ; Labinaz M; Hibbert B
J Am Heart Assoc; 2021 Nov; 10(21):e021570. PubMed ID: 34713704
[TBL] [Abstract][Full Text] [Related]
7. Significant Valvular Dysfunction and Outcomes in Cardiogenic Shock: Insights From the Randomized DOREMI Trial.
Parlow S; Weng W; Di Santo P; Jung RG; Lepage-Ratte MF; Motazedian P; Prosperi-Porta G; Abdel-Razek O; Simard T; Chan V; Labinaz M; Froeschl M; Mathew R; Hibbert B;
Can J Cardiol; 2022 Aug; 38(8):1211-1219. PubMed ID: 35430192
[TBL] [Abstract][Full Text] [Related]
8. Arrhythmic Events and Mortality in Patients With Cardiogenic Shock on Inotropic Support: Results of the DOREMI Randomized Trial.
Jung RG; Di Santo P; Mathew R; Simard T; Parlow S; Weng W; Abdel-Razek O; Malhotra N; Cheung M; Hutson JH; Marbach JA; Motazedian P; Thibert MJ; Fernando SM; Nery PB; Nair GM; Russo JJ; Hibbert B; Ramirez FD
Can J Cardiol; 2023 Apr; 39(4):394-402. PubMed ID: 36150583
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness and Safety Between Milrinone or Dobutamine as Initial Inotrope Therapy in Cardiogenic Shock.
Lewis TC; Aberle C; Altshuler D; Piper GL; Papadopoulos J
J Cardiovasc Pharmacol Ther; 2019 Mar; 24(2):130-138. PubMed ID: 30175599
[TBL] [Abstract][Full Text] [Related]
10. Milrinone vs Dobutamine for the Management of Cardiogenic Shock: Implications of Renal Function and Injury.
Di Santo P; Dehghan K; Mao B; Jung RG; Fadare D; Paydar J; Parlow S; Motazedian P; Prosperi-Porta G; Abdel-Razek O; Joseph J; Goh CY; Chung K; Mulloy A; Ramirez FD; Simard T; Hibbert B; Mathew R; Russo JJ
JACC Adv; 2023 Jul; 2(5):100393. PubMed ID: 38938997
[TBL] [Abstract][Full Text] [Related]
11. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009669. PubMed ID: 29376560
[TBL] [Abstract][Full Text] [Related]
12. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality.
Tarvasmäki T; Lassus J; Varpula M; Sionis A; Sund R; Køber L; Spinar J; Parissis J; Banaszewski M; Silva Cardoso J; Carubelli V; Di Somma S; Mebazaa A; Harjola VP;
Crit Care; 2016 Jul; 20(1):208. PubMed ID: 27374027
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of milrinone and dobutamine in low cardiac output states: Systematic review and meta-analysis.
Mathew R; Visintini SM; Ramirez FD; DiSanto P; Simard T; Labinaz M; Hibbert BM
Clin Invest Med; 2019 Jun; 42(2):E26-32. PubMed ID: 31228965
[TBL] [Abstract][Full Text] [Related]
14. Inotrope and vasopressor use in cardiogenic shock: what, when and why?
Hu K; Mathew R
Curr Opin Crit Care; 2022 Aug; 28(4):419-425. PubMed ID: 35792520
[TBL] [Abstract][Full Text] [Related]
15. Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure.
Rodenas-Alesina E; Luis Scolari F; Wang VN; Brahmbhatt DH; Mihajlovic V; Fung NL; Otsuki M; Billia F; Overgaard CB; Luk A
ESC Heart Fail; 2023 Aug; 10(4):2577-2587. PubMed ID: 37322827
[TBL] [Abstract][Full Text] [Related]
16. Lactate Clearance as a Surrogate for Mortality in Cardiogenic Shock: Insights From the DOREMI Trial.
Marbach JA; Di Santo P; Kapur NK; Thayer KL; Simard T; Jung RG; Parlow S; Abdel-Razek O; Fernando SM; Labinaz M; Froeschl M; Mathew R; Hibbert B
J Am Heart Assoc; 2022 Mar; 11(6):e023322. PubMed ID: 35261289
[TBL] [Abstract][Full Text] [Related]
17. [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
Meissner A; Schmelzle T; Simon R
Z Kardiol; 1996 Nov; 85(11):839-46. PubMed ID: 9064946
[TBL] [Abstract][Full Text] [Related]
18. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.
Unverzagt S; Wachsmuth L; Hirsch K; Thiele H; Buerke M; Haerting J; Werdan K; Prondzinsky R
Cochrane Database Syst Rev; 2014 Jan; (1):CD009669. PubMed ID: 24385385
[TBL] [Abstract][Full Text] [Related]
19. Effects of Inotropes on the Mortality in Patients With Septic Shock.
Sato R; Ariyoshi N; Hasegawa D; Crossey E; Hamahata N; Ishihara T; Nasu M; Devendra G
J Intensive Care Med; 2021 Feb; 36(2):211-219. PubMed ID: 31793373
[TBL] [Abstract][Full Text] [Related]
20. Association between mean arterial pressure during the first 24 hours and hospital mortality in patients with cardiogenic shock.
Burstein B; Tabi M; Barsness GW; Bell MR; Kashani K; Jentzer JC
Crit Care; 2020 Aug; 24(1):513. PubMed ID: 32819421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
